Analysis of an Individualised Stepwise Approach to Non-Pharmacological Therapy in COVID-19.
Acute respiratory failure
Critical care
Hypoxaemia
Intensive care unit
coronavirus
Journal
Respiration; international review of thoracic diseases
ISSN: 1423-0356
Titre abrégé: Respiration
Pays: Switzerland
ID NLM: 0137356
Informations de publication
Date de publication:
2023
2023
Historique:
received:
15
06
2023
accepted:
21
07
2023
medline:
25
9
2023
pubmed:
6
9
2023
entrez:
5
9
2023
Statut:
ppublish
Résumé
Early intubation versus use of conventional or high-flow nasal cannula oxygen therapy (COT/HFNC), continuous positive airway pressure (CPAP), and non-invasive ventilation (NIV) has been debated throughout the COVID-19 pandemic. Our centre followed a stepwise approach, in concordance with German national guidelines, escalating non-invasive modalities prior to invasive mechanical ventilation (IMV) or extracorporeal membrane oxygenation (ECMO), rather than early or late intubation. The aims of the study were to investigate the real-life usage of these modalities and analyse patient characteristics and survival. A retrospective monocentric observation was conducted of all consecutive COVID-19 hospital admissions between March 2020 and December 2021 at a university-affiliated pulmonary centre in Germany. Anthropometric data, therapy, and survival status were descriptively analysed. From 1,052 COVID-19-related admissions, 835 patients were included (54% male, median 58 years). Maximum therapy was as follows: 34% (n = 284) no therapy, 40% (n = 337) COT, 3% (n = 22) HFNC, 9% (n = 73) CPAP, 7% (n = 56) NIV, 4% (n = 34) IMV, and 3% (n = 29) ECMO. Of 551 patients treated with at least COT, 12.3% required intubation. Overall, 183 patients required intensive unit care, and 106 (13%) died. Of the 68 patients who received IMV/ECMO, 48 died (74%). The strategy for non-pharmacological therapy was individual but remained consistent throughout the studied period. This study provides valuable insight into COVID-19 care in Germany and shows how the majority of patients could be treated with the maximum treatment required according to disease severity following the national algorithm. Escalation of therapy modality is interlinked with disease severity and thus associated with mortality.
Sections du résumé
BACKGROUND
Early intubation versus use of conventional or high-flow nasal cannula oxygen therapy (COT/HFNC), continuous positive airway pressure (CPAP), and non-invasive ventilation (NIV) has been debated throughout the COVID-19 pandemic. Our centre followed a stepwise approach, in concordance with German national guidelines, escalating non-invasive modalities prior to invasive mechanical ventilation (IMV) or extracorporeal membrane oxygenation (ECMO), rather than early or late intubation.
OBJECTIVES
The aims of the study were to investigate the real-life usage of these modalities and analyse patient characteristics and survival.
METHOD
A retrospective monocentric observation was conducted of all consecutive COVID-19 hospital admissions between March 2020 and December 2021 at a university-affiliated pulmonary centre in Germany. Anthropometric data, therapy, and survival status were descriptively analysed.
RESULTS
From 1,052 COVID-19-related admissions, 835 patients were included (54% male, median 58 years). Maximum therapy was as follows: 34% (n = 284) no therapy, 40% (n = 337) COT, 3% (n = 22) HFNC, 9% (n = 73) CPAP, 7% (n = 56) NIV, 4% (n = 34) IMV, and 3% (n = 29) ECMO. Of 551 patients treated with at least COT, 12.3% required intubation. Overall, 183 patients required intensive unit care, and 106 (13%) died. Of the 68 patients who received IMV/ECMO, 48 died (74%). The strategy for non-pharmacological therapy was individual but remained consistent throughout the studied period.
CONCLUSIONS
This study provides valuable insight into COVID-19 care in Germany and shows how the majority of patients could be treated with the maximum treatment required according to disease severity following the national algorithm. Escalation of therapy modality is interlinked with disease severity and thus associated with mortality.
Identifiants
pubmed: 37669641
pii: 000533522
doi: 10.1159/000533522
pmc: PMC10614468
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
833-842Informations de copyright
© 2023 The Author(s). Published by S. Karger AG, Basel.
Références
Afr J Thorac Crit Care Med. 2022 Sep 16;28(3):
pubmed: 36426196
Lancet Respir Med. 2020 Dec;8(12):1201-1208
pubmed: 32861276
J Thorac Dis. 2022 May;14(5):1319-1331
pubmed: 35693592
Dtsch Arztebl Int. 2020 Aug 3;117(31-32):528-533
pubmed: 32900426
Lancet Respir Med. 2020 Apr;8(4):e19
pubmed: 32105633
Respir Res. 2020 Jul 28;21(1):198
pubmed: 32723327
N Engl J Med. 2020 Dec 17;383(25):2451-2460
pubmed: 32412710
Crit Care Explor. 2023 Feb 13;5(2):e0863
pubmed: 36817964
ERJ Open Res. 2021 Mar 15;7(1):
pubmed: 33738306
Am J Respir Crit Care Med. 2017 Feb 15;195(4):438-442
pubmed: 27626833
JAMA. 2020 Jun 9;323(22):2329-2330
pubmed: 32329799
Lancet Respir Med. 2020 May;8(5):475-481
pubmed: 32105632
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
Am J Respir Crit Care Med. 2020 May 15;201(10):1299-1300
pubmed: 32228035
Sci Rep. 2022 Jul 1;12(1):11116
pubmed: 35778464
Am J Respir Crit Care Med. 2021 Oct 15;204(8):991-994
pubmed: 34283685
PLoS One. 2022 Jan 14;17(1):e0262315
pubmed: 35030205
Cureus. 2023 Jan 26;15(1):e34249
pubmed: 36855494
J Intensive Care Med. 2023 Jul;38(7):635-642
pubmed: 36803290
Iran J Med Sci. 2022 May;47(3):194-209
pubmed: 35634520
Am J Respir Crit Care Med. 2020 Jul 1;202(1):1-4
pubmed: 32402207
Med Klin Intensivmed Notfmed. 2020 Dec;115(Suppl 3):111-114
pubmed: 32291505
Crit Care. 2021 Mar 25;25(1):121
pubmed: 33766109
Pneumologie. 2020 Jun;74(6):337-357
pubmed: 32323287
Clin Imaging. 2021 Dec;80:229-238
pubmed: 34364071
Eur Respir J. 2021 Feb 17;57(2):
pubmed: 33033151
Crit Care. 2021 Jun 14;25(1):211
pubmed: 34127027
JAMA. 2020 Jul 7;324(1):57-67
pubmed: 32496521
Chest. 2020 Nov;158(5):1992-2002
pubmed: 32681847
Ann Emerg Med. 2020 May;75(5):615-626
pubmed: 31864728
Lancet Respir Med. 2020 Sep;8(9):853-862
pubmed: 32735842